Elicio Therapeutics (ELTX) Net Income (2020 - 2026)

Elicio Therapeutics has reported Net Income for 7 years, with the latest figure at -$10.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income fell 1.4% year-over-year to -$10.9 million; the trailing twelve-month figure through Mar 2026 stood at -$38.4 million (up 15.64% YoY), and the FY2025 full-year result was -$38.8 million, up 14.51% from the prior year.
• Net Income for Q1 2026 stood at -$10.9 million, down from -$9.2 million in the prior quarter.
• The five-year high for Net Income was -$6.0 million in Q4 2022, with the low at -$14.5 million in Q1 2022.
• Historically, Net Income has averaged -$9.7 million across 5 years, with a median of -$10.1 million in 2025.
• The largest YoY upside for Net Income was 59.99% in 2022 against a maximum downside of 140.99% in 2022.
• Elicio Therapeutics' Net Income stood at -$6.0 million in 2022, then tumbled by 55.37% to -$9.3 million in 2023, then slumped by 47.12% to -$13.7 million in 2024, then jumped by 33.05% to -$9.2 million in 2025, then dropped by 18.23% to -$10.9 million in 2026.
• The last three Net Income figures came in at -$10.9 million (Q1 2026), -$9.2 million (Q4 2025), and -$8.3 million (Q3 2025), per Business Quant data.